Clinical Trial Update: RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial evaluated everolimus (RAD001) in combination with cetuximab and cisplatin for recurrent and metastatic head and neck cancer; the study was t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• CISPLATIN (cisplatin)
• Cetuximab (cetuximab)
• Everolimus (everolimus)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Head and Neck Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2014-06-09